Analyzing Biometra And The Industry

1. What is the brief history of the company and its line of business is it involved in?

b. What are the weaknesses or limitations in this analysis? How might they be corrected or reduced?

Two years later, the company launched a recombinant form of Ceredase and started to enter new markets—surgical, pharmaceutical, diagnostic, and genomic products—through strategic alliances, joint ventures, and acquisitions. Such diversity allowed Genzyme to play a leadership role in a broad range of cutting-edge technologies and therapies, according to Genzyme’s chair, president, and CEO, Henri A. Termeer.2 The company’s diversity came from its threea divisions—Genzyme General; Genzyme Tissue Repair; and a subsidiary, Genzyme Transgenics—each with its own common stock traded on the NASDAQ (Exhibit 1).

The pharmaceutical industry is considered to be on of the fastest growing sectors in America. The IMS Institute for Healthcare Informatics reported revenues of $424.8 billion in 2015, a 12.2 percent increase from last year (pharma commerce). Furthermore, the U.S. pharmaceutical industry is considered to be a worldwide leader with sales accounting for approximately 44.5 percent of global sales (Whiteside, 2016). The driving force of these revenue figures is Big Pharma –the largest pharmaceutical companies in the United States. In fact, Pfizer, Merck & Co., and Johnson and Johnson [J&J] are three American companies ranked at the top of the global pharmaceutical market (Dezzanni, 2016).

The company that I chose for the project is Clariant Corporation, I am currently working at Clariant as an outside sales representative for the plastic and coatings division. Clariant is a specialty chemicals company, within Clariant there are four major business areas: chemicals (consumer and industrial), catalysis (natural resources), oil & mining, minerals and plastics & coatings. These four business within Clariant also hold many different segments that are constantly growing and changing with new product lines (Clariant, 2016).

v. Based on the results of the pilot test, identify the strengths and weaknesses of your interview protocol.

Given what you know of the personality under examination, explain which theory or theories of motivation would be most effective for a manager to use when trying to help this individual achieve her or his full potential at work. Describe the process of determination and the theory or theories you eventually recommend, and explain how the manager can use the tenets of that theory or those theories as applied to the person who serves as your case study.

As of the text, one of the strength is to change the environment. It directly leads to lack of dynamic capability. According to “Teece, D.J, Pisana, G, and Shuan.A (1997) the dynamic capabilities is

It has product category and sub categories. In simple way we can say that market size actually can defined as volume and valuation of given product over particular geographical area and market size depend upon few interesting thing like technologies and new scope. It is Year of year rise in growth .Market size also bring the realistic report for the product category will

well. For example, offshore IT workers in this case study could not be relied upon

There are many challenges faced by companies in the Bionanotechnology sector depending on their size.

The five external drivers for this industry are demand from chocolate, per capita disposable income, Per capita sugar and sweetener consumption, price of sugar, and trade-weight index. These five factors have a direct impact on competitors in the industry, this level of competition makes barriers to entering the market medium and

Strengths:  - BVS has assured its relative independence from its corporate  parent in the US - number 2 in its field.  - The hiring effort focused on scientists, and junior  management. - Aggressive investment in Research; Strong and innovative  R&D Department.  - Intensive growth in current sales and projected sales  - Dynamic, entrepreneurial, and ambitious head of purchasing department and have an international experience.  - High-tech machinery, BVS most advanced on the market. - BVS sustain good relations with their supplier.   Opportunities:  - Forceful investments in the pharmaceutical industry, 

“The business is focused around the delivery of three strategic priorities which aim to increase growth, reduce risk, and improve our long-term financial performance. These priorities are: grow a diversified global business, deliver more products of value, and simplify the operating model.” (GSK 2015) The company works to diversify by creating a more balance business and product portfolio that will ensure sustainable sales growth. The company produces and distributes pharmaceuticals, vaccines, and consumer healthcare. The have redesigned research and development so it will be able to sustain an array of products that offer valuable improvements in treatment for patients and healthcare providers. They want to simplify the operating model by reducing complexity and becoming more efficient. They have a mission of being responsible in their delivery strategy to achieve success.

People who work in the information technology (IT) area of a biopharmaceutical company usually start either with an IT background and become interested in the biopharma field, perhaps because of the desire to help find cures for diseases, or they start in the clinical area and become more interested and involved in what IT can do for clinical research. Very few people actually start with the idea of working in IT for a biopharma company. This article focuses on the impact some of the major technologies introduced into the biopharma arena over the past few years. It also addresses IT-oriented clinical research professional needs to know about the various and numerous technologies in this field. And this article will suggest the need for “bridge people” who understand the industry, IT, and how to apply IT to the day-to-day needs of clinical research. Technology is an area of rapid change. It is an area where strong skills and the desire to keep up with innovation and change are essential for a good IT professional and/or bridge person. Although the pace of change makes it difficult for any IT-oriented person to keep up with the field, people must have industry knowledge to drive the adoption of new technology. In this day and age, even clinical research professionals who do not desire to become IT or bridge people must have an improved understanding of technological changes that will help them perform day-to-day work, as this work can no longer be divorced from the technology.